Регистрация
Расширенный поиск
RU EN
Главная
Последний номер
Архив номеров
Подписка
Контакты
Российское диализное общество

Просмотр статьи

<< Вернуться к списку статей журнала

Том 1 №2,3 1999 год - Нефрология и диализ

Вирусные гепатиты. Особенности в условиях заместительной терапии хронической почечной недостаточности Лекция, часть 2


Зубкин М.Л.

Аннотация: Первая часть лекции была опубликована в предыдущем номере журнала [1]. В ней были рассмотрены современные представления о вирусных гепатитах В и D, а также вопросы, связанные с особенностями течения этих заболеваний в условиях заместительной терапии хронической почечной недостаточности (ХПН). В представляемой второй части лекции обсуждаются вопросы эпидемиологии и течения гепатита С, его особенностей в условиях лечения терминальной ХПН, а также проблемы профилактики и лечения вирусных гепатитов с парентеральным механизмом инфицирования.

Для цитирования: Зубкин М.Л. Вирусные гепатиты. Особенности в условиях заместительной терапии хронической почечной недостаточности Лекция, часть 2. Нефрология и диализ. 1999. 1(2,3):107-117. doi:

Весь текст



Ключевые слова: гепатит С, гепатиты с парентеральным механизмом инфицирования, эпидемиология, маркеры, течение, лечение, профилактика, заместительная терапия хронической почечной недостаточности

Список литературы:
  1. Зубкин М.Л. Вирусные гепатиты. Особенности в условиях заместительной терапии хронической почечной недостаточности. Нефрология и диализ 1999; 1: 4-11.
  2. Львов Д.К., Миширо С., Селиванов Н.А. и соавт. Распространение генотипов вируса гепатита С, циркулирующих на территории Северо-Западной и Центральной частей России. Вопросы вирусологии 1995; 5: 251-253.
  3. Львов Д.К., Самохвалов Е.И., Миширо С. и соавт. Закономерности распространения вируса гепатита С и его генотипов в России и странах СНГ. Вопросы вирусологии 1997; 4: 157-161.
  4. Савин Е.А. Вирусные гепатиты (частные аспекты проблемы). Санкт-Петербург: Наука, 1996.
  5. Соринсон С.Н. Вирусные гепатиты A, B, C, D, E, ни A-E в клинической практике. Санкт-Петербург: Теза, 1996.
  6. Aach R.D., Stevens C.E., Hollinger F.B. et al. Hepatitis C virus infection in post-transfusion hepatitis. N Engl J Med 1991; 325: 1325-1329.
  7. Alberti A., Morsica G., Chemello L. et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992; 340: 697-698.
  8. Alexander G.J.M., Brahm J., Fagan E.A. et al. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet 1987; 2: 66-69.
  9. Alter H.J., Purcell R.H., Shih J.W. et al. Detection of antibody to hepatitis C virus in prospectivly followed transfussion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1494-1500.
  10. Alter H.J. Chronic consequences of non-A, non-B hepatitis. In: Current perspectives in hepatology, (ed. Seeff LB). New York: Plenum Medical Books, 1989: 83-97.
  11. Alter M.J., Favero M.S., Maynard J.E. Impact of infection control strategies on the incidence of dialysis-associated hepatitis in the United States. J Infect Dis 1986; 153: 1149-1151.
  12. Alter M.J., Margolis H.S., Krawczynski K. et al. The natural history of community-acquired hepatitis C in the Unite States. N Engl J Med 1992; 327: 1899-1905.
  13. Bailey G.L., Katz A.I., Hampers C.L., Merrill J.P. Alterations in serum enzymes in chronic renal failure. JAMA 1970; 213: 2263-2265.
  14. Bekkering F., Brower J., Leroux-Roels G. et al. Ultrarapid hepatitis C virus clearance by daily higt dose interferon in non-responders to standart therapy. Hepatology 1997; 26, 4, Pt 2, 1147, 415A.
  15. Benhamou E., Courouce A.M., Jungers P. et al. Hepatitis B vaccine: randomized trial in immunogenicity in hemodialysis patients. Clin Nephrol 1984; 21: 143-147.
  16. Benvegnu L., Fattovich G., Chemello L. et al. Reduced incidence of hepatocellular carcinoma (HCC) in cirrhotic patients treated with alpha interferon. IX Triennal International Symposium on Viral Hepatitis and Liver Disease, Rome (abstract volume) 1996; 307.
  17. Boker K.H., Ringe B., Kruger M. et al. Prostaglandin E plus famciclovir - a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation 1994; 57: 1706-1708.
  18. Booth J.C.L. Chronic hepatitis C: the virus, its discovery and the natural history of the disease. J Vir Hepat 1998; 5: 213-222.
  19. Brillanti S., Garson J., Foli M. et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa - resistant chronic hepatitis C. Gastroenterol 1994; 107: 812-817.
  20. Brillanti S., Masci K., Miglioli M., Barbara L. Serum IgM antibodies to hepatitis C virus in acute and chronic hepatitis C. Arch Virol 1993; (suppl. 8): 213-218.
  21. Bukh J., Wantzin P., Krog sgaard K. et al. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: Failure of commercially available antibody tests to identify a significant number of patients with HCV infection. J Infect Dis 1993; 168: 1343-1348.
  22. Cahen D.L., Van Leeuwen D.J., ten Kate F.J.W. et al. Do serum ALAT values reflect the inflammаtory activity in the liver of patients with chronic viral hepatitis. Liver 1996; 16: 105-109.
  23. Caramelo C., Navas S., Alberola M.L. et al. Evidence against transmission of hepatitis C virus through hemodialysis ultrafiltrate and peritoneal fluid. Nephron 1994; 66: 470-473.
  24. Caramelo C., Ortiz A., Aguilera B. et al. Liver disease patterns in hemodialysis patients with antibodies to hepatitis C virus. Am J Kidney Dis 1993; 22: 822-828.
  25. Chan T.M., Lau J.Y.N., Wu P.-C. et al. Hepatitis C virus genotypes in patients on renal replacement therapy. Nephrol Dial Transplant 1998; 13: 731-734.
  26. Chan T.M., Lok A.S.F., Cheng I.K.P., Chan R.T. A prospective study of hepatitis C virus infection among renal transplant recipients. Gastroenterology 1993; 104: 862-868.
  27. Chan T.M., Lok A.S.F., Cheng I.K.P., Ng I.O.L. Chronic hepatitis C after renal transplantation. Treatment with alpha-interferon. Transplantation 1993; 56: 1095-1098.
  28. Chan T.M., Wu P.C., Lau J.Y.N. et al. Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol Dial Transplant 1997; 12: 1414-1419.
  29. Chemello L., Bonetti P., Cavalletto L. et al. Randomized trial comparing three different regiments of alpha-2a interferon in chronic hepatitis C. Hepatology 1995; 22: 700-706.
  30. Chemello L., Cavalletto I., Bernardinello E. et al. Response to ribavirin, to interferon and to a combination of both in patients with chronic hepatitis C and its relation to HCV genotypes. Hepatology 1994; 21: (suppl.1): S12 (abstr.).
  31. Chen K.S., Lo S.K., Lee N. et al. Superinfection with hepatitis C virus in hemodialysis patients with hepatitis B surface antigenemia: its prevalence and clinical significance in Taiwan. Nephron 1996; 73: 158-164.
  32. Choo Q.L., Kuo G., Weiner A.J. et al. Isolation of a cDNA clone derived from blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 358-362.
  33. Chow W.C., Marcellin P., Boyer N. et al. Interferon retreatment in chronic hepatitis C (CHC) patients after a standard course of interferon therapy. Hepatology 1996; 24 (suppl 2): 274A (abstr).
  34. Cohen G.A., Goffinet J.A., Donabedian R.K., Conn H.O. Observations on decreased serum glutamic oxaloacetic transaminase (SGOT) activity in azotemic patients. Ann Intern Med 1976; 84: 275-280.
  35. Colleoni N., Bucci R., Ribero M.L. et al. Hepatitis C virus genotype in anti-HCV-positive hemodialysis patients. Nephrol Dial Transplant 1996; 11: 2258-2264.
  36. Corouce A.M., Pillonell J. Viral Hepatitis Working Groups of the French Society of Blood Transfusion: transfusion - transmitted viral infections. N Engl J Med 1996; 335: 1609-1610.
  37. Craxi A., Di marco V., Lo Iaocono O. et al. Transfusion-associated chronic hepatitis C: alpha-n1 interferon for 6 vs 12 months. Hepatology 1996; 24: 539-546.
  38. Crosnier J., Degos F., Jungers P. Dialysis associated hepatitis. In: Replacement of renal function by dialysis (ed. Maher JF) Dordrecht: Kluwer Academic, 1989: 881-903.
  39. Degos F., Grunfeld J.-P. Liver disease and the kidney. In: Oxford Textbook of Clinical Nephrology. (ed. Davison AM, Cameron JS, Grunfeld J- P et al.) Oxford, New York, Tokyo: Oxford University Press, 1998: 2737-2743.
  40. Delle Volpe M., Caraccio V., Iberti M. et al. Hepatitis B vaccine in dialysed patients: persistence of antibody titres after 48-month follow-up. Minerva Urol Nefrol 1996; 48: 47-50.
  41. Desmyter J., De Groote G., Colaert J. et al. Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Lancet 1983; 2: 1323-1328.
  42. Di Bisceglie A.M., Goodman Z.D., Ishak K.G. et al. Long-term clinical and hystopathological follow-up of clinical post-transfusion hepatitis. Hepatology 1991; 14: 969.
  43. Dienstag J.L., Perrillo R.P., Schiff F.R. et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-1661.
  44. Dienstag J.L., Schiff F.R., Gitlin N. et al. Extended lamivudine retreatment for chronic hepatitis B. Hepatology 1996; 24: suppl.: 188A (abstr.).
  45. Dodd R.Y., Popovsky M.A. and members of the Scientific Section Coordinating Committee. Antibody hepatitis core antigen and the infectivity of the blood supply. Transfusion 1991; 31: 443-449.
  46. Doherty C.C., Girndt M., Gerken G., Kohler H. The patient with failing renal function. Hepatitis. In: Oxford Textbook of Clinical Nephrology. (ed. Davison AM, Cameron JS, Grunfeld J- P et al.) Oxford, New York, Tokyo: Oxford University Press, 1998: 1924-1935.
  47. dos Santos J.P., Loureiro A., Neto S.M. et al. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in hemodialysis units. Nephrol Dial Transplant 1996; 11: 2017-2022.
  48. Dusheiko J.M. New treatments for chronic viral hepatitis B. In: Therapy in liver disease. The pathophysiological Basis of Therapy. (ed. Arroyo V, Bosch J, Bruguera M, Rodes J) Barcelona, Madrid, Paris: Masson, S.A. 1997; 317-330.
  49. Farci P., Mandas A., Coiana A. et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994; 330: 88-94.
  50. Fritsche C., Brandes J.C., Delaney S.R. et al. Hepatitis C is poor prognostic indicator in black kidney transplant recipients. Transplantation 1993; 55: 1283-1287.
  51. Geerlings W., Tufveson G., Ehrich J.H. et al. Report on Management of Renal Failure in Europe, XXIII. Nephrol Dial Transplant 1994; 9, (Suppl. I): 6-25.
  52. Gilli P., Soffritti S., De PaolimVitali E., Bedani P.L. Prevention of hepatitis C virus in dialysis units. Nephroh 1995; 70: 301-306.
  53. Goffin E., Pirson Y., van Ypersele de Strihou. Implications of chronic hepatitis B or hepatitis C infection for renal transplant candidates. Nephrol Dial Transplant 1995; 10 (suppl.6): 88-92.
  54. Goffin E., PirsonY., Cornu C. et al. Outcome of HCV infection after renal transplantation. Kidney Int 1994; 45: 551-555.
  55. Greenberg H., Pollard R., Lutwick L. et al. Effect of human leucocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976; 295: 517-522.
  56. Guh J.Y., Lai Y.H., Yang C.Y. et al. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron 1995; 69: 459-465.
  57. Hakim R.M., Lazarus J.M. Biochemical parameters in chronic renal failure. Am J Kidney Dis 1988; 11: 238-247.
  58. Harihara Y., Kurooka Y., Yanagisawa T. et al. Interferon therapy in renal allograft recipients with chronic hepatitis C. Transplant Proc 1994; 26: 2075.
  59. Haubitz M., Ehlerding G., Beigel A. et al. Clinical experience with a new recombinant hepatitis-B vaccine in previous non-responders with chronic renal insufficiency. Clin Nephrol 1996; 45: 180-182.
  60. Heaf J.G. Liver function tests and pyridoxine levels in uremia. Nephron 1982; 30: 131-136.
  61. Hess G., Kreiter F., Kosters W., Deusch K. The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients. J Vir Hepat 1996; 3: 149-153.
  62. Hess G., Massing A., Rossol S. et al. Hepatitis C virus and sexual transmission. Lancet 1989; 334: 987.
  63. Hestin D., Guillemin F., Castin N. et al. Pretransplant hepatitis C virus infection. Transplantation 1998; 65: 741-744.
  64. Honda M., Kaneko S., Sakai A. et al. Degree of diversity of hepatitis C virus quasispecies and progression of liver disease. Hepatology 1994; 20: 1144-1149.
  65. Hoofnagle J.H., Di Bisceglie A.M. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-356.
  66. Hoofnagle J.H. Therapy of acute and chronic viral hepatitis. Adv Intern Med 1994; 39: 241-275.
  67. Houghton M., Weiner A., Han J. et al. Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease. Hepatology 1991; 14: 381-388.
  68. Hsu H., Wright T., Luba D. et al. Failure to detect hepatitis C virus genome in human secretions with the polymerase chain reaction. Hepatology 1991; 14: 763-767.
  69. Hwang S.J., Lee S.D., Chan C.Y. et al. A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. Hepatology 1994; 21: 831-836.
  70. Jadoul M., Cornu S., van Ypersele de Strihou C., UCL Collaborative Group. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian multicenter study. Kidney Int 1998; 53: 1022-1025.
  71. Jadoul M. Should hemodialysed patients with hepatitis C virus antibodies be isolated? Semin in Dialysis 1995; 8: 1-3.
  72. Jeffers L.J., Perez G.O., de Medina M.D. et al. Hepatitis C infection in two urban hemodialysis units. Kidney Int 1990; 38: 320-322.
  73. Jungers P., Chauveau P., Courouce A.M. et al. Immunogenicity of the recombinant Genhevac B Pasteur Vaccine aginst hepatitis B in chronic uremic patients. J Infect Dis 1994; 169: 399-402.
  74. Jungers P., Chauveau P., Loubaris T. et al. Immune response to hepatitis B vaccine in chronic uremic patients. In: Progress in hepatitis B immunization, (ed. Coursaget P and Tong MJ) Colloque INSERM, John Libbey Eurotext, 1990; 194: 187-195.
  75. Jungers P., Devillier P., Salomon H. et al. Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uremic patients who are non-responders to hepatitis B vaccine. Lancet 1994; 344: 856-857.
  76. Kahns M., de Medina M., McNamara A. et al. Detection of hepatitis C virus RNA in hemodialysis patients. J Am Soc Nephrol 1994; 4: 1491-1497.
  77. Kao J.H., Chen P.J., La My, Chen D.S. Superinfection of heterologous hepatitis C virus in a patient with chronic type C hepatitis. Gastroenterol 1993; 105: 583-587.
  78. Khan A.N., Bernardini J., Rault R.M., Piraino B. Low seroconversion with hepatitis B vaccination in peritoneal dialysis patients. Perit Dial Int 1996; 16: 370-373.
  79. Kiyosawa K., Sodeyama T., Tanaka E. et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-675.
  80. Klein M., Geoghegan I., Schmidt K. et al. Conversion of recurrent delta-positive hepatitis infection to seronegativity with famciclovir after liver transplantation. Transplantation 1997; 64: 162-163.
  81. Kliem V., van den Hoff U., Brunkhorst R. et al. The long-term course of hepatitis C after kidney transplantation. Transplantation 1996; 62: 1417-1421.
  82. Koenig P., Vogel W., Umlauft F. et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 1994; 45: 1507-1509.
  83. Kohler H. Hepatitis B immunisation in dialysis patients is it worthwhile? Nephrol Dial Transplant 1994; 9: 1719-1720.
  84. Koizumi K., Enomoto N., Kurosaki M. et al. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 1995; 22: 30-32.
  85. Kurz P., Kohler H., Meuer S. et al. Impaired cellular immune responses in chronic renal failure: evidence for a T cell defect. Kidney Int 1986; 29: 1209-1213.
  86. Lai C.-L., Chien R.-N., Leung N.W.Y. et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-68.
  87. Lai M.E., Mazzoleni A.P., Argiolu F. et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1993; 343: 388-390.
  88. Lam N., Neumann A., Gretch D. et al. Dosedependent acute clearance of hepatitis C genotype 1 virus with interferon alpha. Hepatology 1997; 26: 226-231.
  89. Lee W.M. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745.
  90. Legendre C., Garrigue V., Le Bihan C. et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998; 65: 667-670.
  91. Lin R., Roach E., Zimmerman M. et al. Interferon a-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Hepatology 1995; 23: 487-496.
  92. Loch T., Kozlowska J., Cianciara J. et al. Procollagen-III peptide in chronic hepatitis type B and C treated with interferon alpha. Follow up study. Hepatology 1997; suppl.1, 26, CO1/163: 218.
  93. Lok A.S.F., Ghany M.G., Watson G., Ayola B. Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. J Vir Hepat 1998; 5: 171-178.
  94. Lok A.S.F., Wu P.-C., Lai C.-L. et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterol 1992; 102: 2091-2097.
  95. Lombardi M., Cerrai T., Dattolo P. et al. Is the dialysis membrane a safe barrier against HCV infection? Nephrol Dial Transplant 1995; 10: 578-579.
  96. Manzini P., Amore A., Bonaudo R. et al. Is HCV RNA detectable in the ultrafiltrate? Minerva Urol Nefrol 1996; 48: 75-79.
  97. Marangi A.L., Giordano R., Montanaro A. et al. Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated protocol of vaccination. Am I Kidney Dis 1994; 23: 537-542.
  98. Marcellin P., Boyer N., Giostra E. et al. Recombinant human alpha interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991; 13: 393-367.
  99. Marcellin P., Boyer N., Martinot M., Erlinger S. Interferon therapy in hepatitis C: benefits and limitations. In: Therapy in liver disease. The pathophysiological Basis of Therapy. (ed. Arroyo V, Bosch J, Bruguera M, Rodes J) Barcelona, Madrid, Paris: Masson, S.A. 1997: 309-316.
  100. Martin P., Friedman L.S. Chronic viral hepatitis and the management of chronic renal failure. Kidney Int 1995; 47: 1231-1241.
  101. Mazzella G., Accogli E., Sottili S. et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. Hepatology 1996; 24: 141-147.
  102. McIntyre P.G., McCruden E.A., Dow B.C. et al. Hepatitis C virus infection in renal dialysis patients in Glasgow. Nephrol Dial Transplant 1994; 9: 291-295.
  103. McLaughlin K.J., Cameron S.O., Good T. et al. Nosocomial transmission of hepatitis С virus within British dialysis center. Nephrol Dial Transplant 1997; 12: 304-309.
  104. Meuer S.C., Dumann H., Meyer zum Buschenfelde K.H., Kohler H. Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet 1989; i: 15-18.
  105. MMWR Update. Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus and bloodborne pathogens in health-care setting. JAMA 1988; 260: 462-465.
  106. Morales J.M., Campistol J.M., Castellano G. et al. Transplantation of kidneys from donors with hepatitis C antibodies into recipients with pre-transplantation anti-HCV. Kidney Int 1995; 47: 236-240.
  107. Morales J.M., Munoz M.A., Castellano G. et al. Impact of hepatitis C in long-functioning renal transplants: a clinicopathological follow-up. Transplant Proc 1993; 25: 1450-1453.
  108. Moyer L.A., Alter M.J. Hepatitis C virus in the hemodialysis setting: A review with recommendations for control. Semin in Dialysis 1994; 7: 124-127.
  109. Muller G.Y., Zabaleta M.E., Arminio A. et al. Risk factors for dialysis-associated hepatitis C in Venezuela. Kidney Int 1992; 41: 1005-1008.
  110. Nanji A.A., Decreased activity of commonly measured: cause and clinical significance. Am J Med Technol 1983; 49: 241-245.
  111. Nasoff M.S., Zebedee S.L., Inchauspe G., Prince A.M. Identification of an immunodominant epitope within the capsid protein of hepatitis C virus. Proc Natl Acad Sci USA 1991; 88: 5462-5466.
  112. Neto M.C., Draibe S.A., Silva A.E.B. et al. Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among hemodialysis and CAPD patients: evidence for environmental transmission. Nephrol Dial Transplant 1995; 10: 240-246.
  113. Nishiguchi S., Kuroki T., Nakatani S. et al. Randomised trial of effects of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055.
  114. Niu M.T., Coleman P.J., Alter M.J. Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members. Am J Kidney Dis 1993; 22: 568-573.
  115. Oguchi H., Miyasaka M., Tokunaga S. et al. Hepatitis virus infection (HBV and HCV) in eleven Japanese hemodialysis units. Clin Nephrol 1992; 38: 36-43.
  116. Oliva J.A., Ercilla G., Mallafre J.M. et al. Markers of hepatitis C infection among hemodialysis patients with acute and chronic infection: Implications for infection control strategies in hemodialysis units. Int J Artif Org 1995; 18: 73-77.
  117. Olmer M., Bouchouareb D., Zandotti C. et al. Transmission of the hepatitis C virus in hemodialysis unit: evidence for nosocomial infection. Clin nephrol 1997; 47: 263-270.
  118. Omata M., Yokosuka O., Takano S. et al. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991; 338: 914-915.
  119. Ono K., Kashiwagi S. Complete seroconversion by low-dose intradermal injection of recombinant hepatitis B vaccine in haemodialysis patients. Nephron 1991; 58: 47-51.
  120. Ozgur O., Boyacioglu S., Telatar H., Haberal M. Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C. Nephrol Dial Transplant 1995; 10: 2104-2106.
  121. Paparella M., Tarantino A., Ponticelli C. How to manage the dialysis patient with chronic viral hepatitis who is consider for renal transplantation. Nephrol Dial Transplant 1996; 11: 2122-2124.
  122. Payen J.L., Izopet J., Galindo V. et al. A comparison of three interferon alfa-2b regimens for retreatment (RTT) of patients with chronic hepatitis C with prior complete response followed by relapse: a controlled, randomized trial. Hepatology 1996; 24 (suppl. 2): 273A (abstr).
  123. Peces R., de la Torre M., Alcazar R., Urra J.M. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in haemodialysis patients. Am J Kidney Dis 1997; 29: 239-245.
  124. Pereira B.J.G. Hepatitis C infection in patients on dialysis. Semin Dial 1994; 7: 360-368.
  125. Pereira B.J.G., Levey A.S. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51: 981-999.
  126. Pereira B.J.G., Milford E.L., Kirkman R.L. et al. Prevalence of HCV RNA in hepatitis C antibody positive cadaver organs donors and their recipients. N Engl J Med 1992; 327: 910-915.
  127. Pereira B.J.G., Milford E.L., Kirkman R.L., Levey A.S. Transmission of hepatitis C virus by organ transplantation. N Engl J Med 1991; 325: 454-460.
  128. Pereira B.J.G., Wright T.L., Schmid, Levey A.S. for the New England Organ Bank Hepatitis C Study Group. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60: 799-805.
  129. Perrillo R.P., Schiff E.R., Davis G.L. et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323: 295-301.
  130. Pol S., Romeo R., Zins B. et al. Hepatitis C virus RNA in anti-HCV positive hemodialysed patients: significance therapeutic implications. Kidney Int 1993; 44: 1097-1100.
  131. Pol S., Thiers V., Carnot F. et al. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 1995; 47: 1412-1418.
  132. Ponz E., Campistol J.M., Barrera J.M. et al. Hepatitis C virus antibodies in patients on hemodialysis and after transplantation. Transplant Proc 1991; 23: 1371-1372.
  133. Poynard T., Bedossa P., Chevallier M. et al. A comparison of three interferon a-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 1457-1462.
  134. Rao V.K., Anderson W.R., Kasiske B.L., Dahl D.C. Value of liver biopsy in the evaluation and management of chronic liver disease in renal transplant recipients. Am J Med 1993; 94: 241-250.
  135. Raptopoulou-Gigi M., Spaia S., Garifallos A. et al. Interferon-alpha2b treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant 1995; 10: 1834-1837.
  136. Reichard O., Norkrans J., Fryden A. et al. Interferon-alpha and ribavirin versus interferon-alpha alone as therapy treatment for chronic hepatitis C - a randomized double-blind placebo controlled study. Hepatology 1996; 24: suppl.: 356A (abstr.).
  137. Rizzetto M., Bordghesio E. Interferon therapy for chronic hepatitis B and D: an overview. In: Therapy in liver disease. The pathophysiological Basis of Therapy. (ed. Arroyo V, Bosch J, Bruguera M, Rodes J) Barcelona, Madrid, Paris: Masson, S.A. 1997: 295-300.
  138. Rosina F., Martinotti R., Mattalia A. Recent developments in the treatment of hepatitis D infection. Exp Opin Invest Drugs 1996; 5: 197-205.
  139. Rosina F., Pintus C., Meschievitz C., Rizzetto M. A randomized controlled trial of a 12 month course of recombinant human interferon alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology 1991; 13: 1052-1056.
  140. Rostaing L., Izopet J., Baron E. et al. Preliminary results of treatment chronic hepatitis C with recombinant interferon alpha in renal transplant patients. Nephrol Dial Transplant 1995; 10 (suppl.6): 93-96.
  141. Roth D., Zucker K., Cirocco R. et al. The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int 1994; 45: 238-244.
  142. Sakamoto N., Enomoto N., Marumo F., Sato C. Prevalence of hepatitis C virus infection among long-term hemodialysis patients: Detection of hepatitis C virus RNA in plasma. J Med Virol 1993; 39: 11-15.
  143. Sampietro M., Badalamenti S., Salvadory S. et al. High prevalence of a rare hepatitis C virus in patients treated in the same hemodialysis units: evidence for nosocomial transmission of HCV. Kidney Int 1995; 47: 911-917.
  144. Schlipkoter U., Roggendorf M., Ernst G. et al. Hepatitis C virus antibodies in hemodialysis patients. Lancet 1990; 335: 1409.
  145. Schreiber G.B., Busch M.P., Kleinman S.H., Korelitz J.J. The risk of transfusion - transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334: 1685-1690.
  146. Seeff L.B., Buskell-Bales Z., Wright E.C. et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992; 327: 1906-1911.
  147. Sherlock S., Dooley J. Diseases of the liver and biliary system. Oxford, London, Edinburg, Malden: Blackwell Science Ltd, 1997: 274-335.
  148. Sherman K.E. Alanine aminotransferase in clinical practice - A review. Arch Intern Med 1991; 151: 260-265.
  149. Simmonds P., Alberti A., Alter H.J. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-1324.
  150. Simmonds P., Holmes E.C., Cha T.A. et al. Classification of hepatitis C virus into six major region genotypes and a series subtypes by phylgenetic analysis of the NS5 region. J Gen Virol 1993; 74: 2391-2399.
  151. Simon N., Courouce A.M., Lemarrec N. et al. A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. Kidney Int 1994; 46: 504-511.
  152. Spanish multicentere study group, coordinators Barril G., Traver J.A. Prevalence of hepatitis C virus in dialysis patients in Spain. Nephrol Dial Transplant 1995; 10 (suppl. 6): 78-80.
  153. Stempel C.A., Lake J., Kuo G., Vincenti F. Hepatitis C - its prevalence in end-stage renal failure patients and clinical course after kidney transplantation. Transplantation 1993; 55: 273-276.
  154. Stuyver L., Claeys H., Wyseur A. et al. Hepatitis C virus in hemodailysis unit: molecular evidence for nosocomial transmission. Kidney Int 1996; 49: 889-895.
  155. Tamura I., Kobayashi Y., Koda T. et al. Hepatitis C virus antibody in hemodialysis patients. Lancet 1990; 335: 1409 -1412.
  156. Teder R., Gilson R., Briggs M. et al. Hepatitis C virus: evidence for sexual transmission. Brit Med J 1991; 302: 1299-1302.
  157. Terrault N., Wright T. Interferon and hepatitis C. N Engl J Med 1995; 332: 1509-1513.
  158. Tong M., El-Farra N., Reikes A., Co R. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466.
  159. Tremolada F., Casarin C., Аlberti A. et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. Hepatology 1992; 16: 273-281.
  160. Valderrabano F., Jones E.H.P., Mallick N.P. Report on the management of renal failure in Europe, XXIII. Nephrol Dial Transplant 1995; 10: 1-25.
  161. Van Ness M.M., Diehl A.M. Is liver biopsy useful in evaluation of patients with chronically elevated liver enzymes? Ann Int Med1989; 111: 473-478.
  162. Vlassopoulos D., Arvanitis D., Lilis D. et al. Complete success of intradermal vaccination against hepatitis B in advanced chronic renal failure and haemodialysis patients. Ren Fail 1997; 19: 455-460.
  163. Waite N., Thomson L., Semple J., Goldstein M. Increase of hepatitis B (HB) antibody titre (ABT) by repetitive administration of intradermal (id) HB vaccine in chronic haemodialysis patients. J Am Soc Nephrol 1992; 3: 402.
  164. Ward K.N., Dhaliwal W., Ashworth K.L. et al. Measurment of antibody avidity for hepatitis C virus distinguishes primary antibody responses from passively acquired antibody. J Med Virol 1994; 43: 367-372.
  165. Warnock L.G., Stone W.J., Wagner C. Decreased aspartate aminotransferase (SGOT) activity in serum of uremic patients. Clin Chem 1974; 20: 1213-1216.
  166. Weiner A.J., Brauer M.J., Rosenblatt J. et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991; 180: 842-848.
  167. Wejstal R. Immune-mediated liver damage in chronic hepatitis C. Scand J Gastroenterol 1995; 30: 609-610.
  168. Widell A., Mansson S., Persson N.H. et al. Hepatitis C superinfection in hepatitis C virus (HCV)- infected patients transplanted with an HCV-infected kidney. Transplantation 1995; 60: 642-647.
  169. Wolf P.L., Williams D., Coplon N., Coulson A.S. Low aspartate transaminase activity in serum of patients undergoing chronic hemodialysis. Clin Chem 1972; 18: 567-568.
  170. Wong D.K.H., Cheung A.M., O′Rourke K. et al. Effect of alpha-interferon treatment in patients with hepatitis Be antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 119: 312-323.
  171. Yamaji K., Hayashi J., Kawakami Y. et al. Long term survey of hepatitis C virus infection in hemodialysis units in Fukuoka, Japan. J Epidemiol 1996; 6: 166-171.
  172. Yasuda K., Okuda K., Endo N. и соавт. Hypoaminotransferasemia in patients undergoing long-term hemodialysis: clinical and biochemical appraisal. Gastroenterology 1995; 109: 1295-1300.
  173. Yoshioka K., Kakumu S., Wakita T. et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: Relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293-299.
  174. Zanetti A., Tanzi E., Paccagnini S. et al. Mother-to-infant transmission of hepatitis C virus. Lancet 1995; 345: 289-291.
  175. Zeldis J.B., Depner T.A., Kuramoto I.K. et al. The prevalence of hepatitis C virus antibody among hemodialysis patients. Ann Intern Med 1990; 112: 958-960.
  176. Zoulim F., Haem J., Ahmed S.S. et al. Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. J Vir Hepat 1998; 5: 193-198.

Другие статьи по теме


Навигация по статьям
<< Предыдущая
Следующая >>
Разделы журнала
Наиболее читаемые статьи

Варшавский В.А., Проскурнева Е.П., Гасанов А.Б. и соавт.,  Об уточнении клинико-морфологической классификации хронического гломерулонефрита  1837

Земченков А.Ю., Кондуров С.В., Гаврик С.Л. и соавт.,  Качество жизни пациентов с хронической почечной недостаточностью, корригируемой заместительной терапией Обзор литературы  1618

Бернард Шарра,  Гемодиализ: «сухой вес»; история концепции  1600

Медиана Фильтр (баннер в правом меню) Реклама
Журнал "Нефрология и диализ"
Главная
Последний номер
Архив номеров
Подписка
Контакты
BBraun (нижний баннер) Реклама